Silphium Asset Management Ltd Sells 44,600 Shares of Amedisys, Inc. (NASDAQ:AMED)

Silphium Asset Management Ltd cut its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 37.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,000 shares of the health services provider's stock after selling 44,600 shares during the period. Amedisys comprises approximately 2.2% of Silphium Asset Management Ltd's portfolio, making the stock its 13th biggest holding. Silphium Asset Management Ltd owned about 0.23% of Amedisys worth $6,809,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AMED. Blue Trust Inc. lifted its holdings in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new position in shares of Amedisys in the fourth quarter valued at approximately $38,000. Versant Capital Management Inc increased its holdings in Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after acquiring an additional 183 shares during the period. KBC Group NV purchased a new stake in Amedisys in the 3rd quarter worth approximately $63,000. Finally, Venturi Wealth Management LLC boosted its holdings in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after purchasing an additional 779 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Stephens reaffirmed an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $100.75.

Amedisys Price Performance

AMED stock traded up $0.14 during midday trading on Thursday, reaching $92.17. The company had a trading volume of 177,175 shares, compared to its average volume of 377,359. The firm has a 50-day moving average price of $91.69 and a 200-day moving average price of $93.06. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market capitalization of $3.02 billion, a P/E ratio of 36.58, a P/E/G ratio of 1.78 and a beta of 0.73. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. On average, research analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.